--- title: "HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session" type: "News" locale: "en" url: "https://longbridge.com/en/news/286510086.md" description: "HCW Biologics Inc. (NASDAQ:HCWB) shares surged 122.55% in after-hours trading to $0.75 after reporting Q1 EPS of $0.37, significantly beating the analyst estimate of -$0.44. Revenue rose to $6.5 million, driven by a licensing deal with Beijing Trimmune Biotech. Despite the positive results, the company flagged going-concern doubts and is appealing a Nasdaq delisting determination. HCWB has a market cap of $2.27 million and has dropped 96.17% over the past year." datetime: "2026-05-15T03:21:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286510086.md) - [en](https://longbridge.com/en/news/286510086.md) - [zh-HK](https://longbridge.com/zh-HK/news/286510086.md) --- # HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session **HCW Biologics Inc.** (NASDAQ:HCWB) shares are trending on Thursday night. HCWB shares surged 122.55% to $0.75 in after-hours trading on Thursday after the clinical-stage biopharmaceutical company posted first-quarter results, reporting earnings per share of $0.37, which beat the analyst estimate of -$0.44 by 184.09%. ## Trimmune Deal Powers Revenue Turnaround HCW Biologics reported revenue of $6.5 million for the quarter ended Mar. 31, compared with just $5,065 a year earlier. The increase was driven by the March closing of an exclusive worldwide licensing agreement with **Beijing Trimmune Biotech** for HCW11-006, a multi-functional fusion immunotherapeutic designed to treat solid tumors by activating CD8+ T cells and NK cells. According to the company, the deal included a nonrefundable upfront license fee of $3.5 million in gross cash proceeds and an in-kind payment consisting of a $3.5 million transferable minority equity stake in Trimmune. Net income of the Florida-based company swung to $3.5 million from a loss of $2.2 million in the first quarter of 2025. Research and development expenses and general and administrative expenses also declined 15% and 18%, respectively, reflecting tighter cost controls. ## Phase 1 Data Readout In Focus The company's lead autoimmune asset, HCW9302, is a first-in-class interleukin 2 fusion protein targeting alopecia areata, with no dose-limiting toxicities reported to date. Preliminary Phase 1 data from the first two dose cohorts is expected in the first half of 2026, with a full readout targeted for the fourth quarter of 2026. CEO **Dr. Hing C. Wong** said HCW9302 “has demonstrated relatively high IL-2Rα affinity and sustains serum exposure,” adding that preclinical studies in nonhuman primates show “significantly longer serum half-life and strong biological activity in relatively low doses.” ## What Investors Need To Know Investors should note that as of Mar. 31, the company flagged going-concern doubt over its ability to continue operations for at least 12 months without additional funding. On May 5, the company was also granted a Nasdaq hearing to appeal a delisting determination by staff due to non-compliance with the $1.00 minimum bid price requirement. ## Trading Metrics, Technical Analysis HCW Biologics has a market capitalization of $2.27 million, with a 52-week high of $10.50 and a 52-week low of $0.25. The stock of the biotech has a Relative Strength Index (RSI) of 42.58. Over the past 12 months, HCWB has dropped 96.17%. The small-cap stock is currently trading near its 52-week low. **Price Action:** According to Benzinga Pro data, HCWB closed the regular session at $0.34, down 3.55%. **Benzinga's Edge Stock Rankings** indicate HCWB stock has a negative price trend across all time frames. _Photo Courtesy: Proxima Studio on Shutterstock.com_ **Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. **Read Also: POET Technologies, Cerebras Systems, Applied Materials, Nu Holdings And Figma: Why These 5 Stocks Are On Investors' Radars Today** ### Related Stocks - [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [POET.US](https://longbridge.com/en/quote/POET.US.md) - [AMAT.US](https://longbridge.com/en/quote/AMAT.US.md) - [NU.US](https://longbridge.com/en/quote/NU.US.md) - [FIG.US](https://longbridge.com/en/quote/FIG.US.md) ## Related News & Research - [Why Is Penny Stock HCW Biologics (HCWB) Up Today?](https://longbridge.com/en/news/286637595.md) - [HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | HCWB Stock News](https://longbridge.com/en/news/286463081.md) - [HCW Biologics Q1 revenue surges on licensing deal](https://longbridge.com/en/news/286464528.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)